Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | PYGB | P11216 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22372512 | 0.82 | LGALS8 (0.56) | CA12CA1CA2CA9LGALS3 | |
| SCHEMBL2230624 | 0.82 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL28378672 | 0.82 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL12894485 | 0.82 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL1224787 | 0.82 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL14067604 | 0.78 | CA1 (0.59) | CA12CA1CA2CA9PYGB | |
| SCHEMBL3228008 | 0.78 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL1647661 | 0.78 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL1647658 | 0.78 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL14707760 | 0.78 | PYGB (0.58) | CA12CA1CA2CA9PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-06-23 | — | — | US | disclosed |
| US-7915227-B2 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-03-29 | — | — | US | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | NPC1L1, SGMS2, SGMS1 | CA12 1872/4885CA1 3018/4885CA2 2144/4885 |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | SGMS1, SGMS2, CERT1 | CA12 1285/4885CA1 1967/4885CA2 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.